Remove Food and Drug Administration Remove Leads Remove Marketing Remove Sales
article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. They relied so much on a new drug that they tried to market a product with bad science behind it. The pharma industry is a giant behemoth that needs new drugs to survive and grow.

Pharma 210
article thumbnail

Acute lymphocytic leukaemia leads in cell therapy clinical development

Pharmaceutical Technology

The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

Leads 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Role of Certified Pharmaceutical Representatives in the Shifting Sales Landscape

Pharmaceutical Representative Training

The Role of Certified Pharmaceutical Representatives in the Shifting Sales Landscape The US Bureau of Labor Statistics (BLS) projects the number of jobs for pharmaceutical sales representatives will grow by four percent by 2031, adding approximately 170,000 new job openings per year over this decade.

Sales 52
article thumbnail

Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate

Pharmaceutical Technology

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). upfront payment and eligible for royalties on net sales. CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.

article thumbnail

EndoStim Receives FDA Breakthrough Device Designation for the EndoStim System for the Treatment of Drug Refractory GERD

Legacy MEDSearch

EndoStim , a medical device company developing and commercializing a first-in-class implantable neurostimulation treatment for drug refractory gastroesophageal reflux disease (GERD), announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Company’s EndoStim System.

article thumbnail

Age-related macular degeneration market expected to grow to $22.8bn in 2031

Pharmaceutical Technology

The wAMD and GA markets are anticipated to reach values of $18.8bn and $4.0bn, respectively, in 2031 in the 7MM. The frequency of administration associated with a therapy is a critical factor that companies in this space focus on to fine-tune their chances of success in the wAMD market.

article thumbnail

FDA Authorizes Marketing of MISHA™ Knee System for People Suffering from Knee Osteoarthritis

Legacy MEDSearch

Food and Drug Administration (FDA) granted marketing authorization of the MISHA Knee System, an implantable shock absorber (ISA) for the knee. The post FDA Authorizes Marketing of MISHA™ Knee System for People Suffering from Knee Osteoarthritis appeared first on Legacy MedSearch | Medical Device Recruiters.